Medtronic's Next-Generation Pump Enters Trial Against Current Artificial Pancreas Systems

The ELEVATE study will compare Medtronic's new MiniMed NMX8 pump to today's automated insulin delivery systems in nearly 230 adults with type 1 diabetes. Results could show whether newer technology offers meaningful improvements in blood sugar management.

Video report — unverified, pending corroboration

Evidence label explains the kind of source behind this article (for example peer-reviewed literature vs community video). It is not medical advice.

cure researchbeta cellsadvancements

Key takeaways

Medtronic is testing its MiniMed NMX8 pump, a next-generation device, against current artificial pancreas systems in a pre-market trial called ELEVATE
The study will enroll approximately 230 adults with type 1 diabetes to compare how well the new pump works
This is a randomized trial, meaning participants are assigned by chance to either the new pump or current systems to ensure fair comparison
Results from ELEVATE will help determine whether the MiniMed NMX8 offers advantages over existing automated insulin delivery technology

What Is the ELEVATE Study?

Medtronic has launched a clinical trial called ELEVATE to test its next-generation insulin pump, the MiniMed NMX8, against the automated insulin delivery (AID) systems currently available to people with type 1 diabetes. The study is registered on ClinicalTrials.gov and will recruit approximately 230 adults with type 1 diabetes across multiple sites.

This is a randomized, controlled study, which is the gold standard for comparing medical devices. Participants will be randomly assigned to either use the new MiniMed NMX8 pump or continue with their current artificial pancreas system. By comparing results between the two groups, researchers can determine whether the newer technology delivers real improvements in blood sugar management and quality of life.

Why Compare Pump Systems?

Automated insulin delivery systems have transformed type 1 diabetes management over the past several years, offering people more stable blood sugar levels with less manual work. However, the field continues to evolve. New devices may offer better glucose control, fewer alarms, longer wear time, or easier use—but these benefits need to be tested in real-world conditions with actual patients before they can be proven.

The ELEVATE trial will generate the clinical evidence needed to understand how the MiniMed NMX8 compares to systems already in use. This data helps both patients and healthcare providers make informed decisions about which technology may work best for their needs.

What Happens Next?

As a pre-market study, ELEVATE is being conducted before the MiniMed NMX8 has received final regulatory approval. The results will inform whether the device performs safely and effectively enough to gain approval for widespread use. Type 1 Cure will continue to follow this trial and share findings as they become available.

Evidence label

Origin: T1D Pulse (Video report). Evidence: Video report — unverified, pending corroboration. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

More evidence-labeled coverage across the Type1Cure library.